Clinical trial NCT05333926: MHNA-001 for Young Adults With IBS
Official title: A Prospective, Open-Label Study of Mahana™ IBS, a Smartphone-Delivered Cognitive Behavioral Therapy (CBT) Treatment, in Young Adults Aged 18-21 Years Old With Irritable Bowel Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Irritable Bowel Syndrome
Lead sponsor: Mahana Therapeutics
Sponsor class: INDUSTRY
First posted: 2022-04-19
Enrollment: 194
Sex: ALL
Minimum age (years): 18
Maximum age (years): 21
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ IBS together with care as usual in approximately 100 young adults with Irritable Bowel Syndrome.

Detailed description: Following informed consent, all participants will complete a series of screening questionnaires to determine eligibility for study entry. Eligible participants will be enrolled, and will receive access to MHNA-001 (Mahana™ for IBS). Participants will use MHNA-001 for 12 weeks.

Eligibility criteria: Inclusion Criteria:

* Participant meets IBS diagnostic criteria via Rome IV questionnaire.
* Participant has IBS, based on IBS-SSS score of ≥125 at time of screening (corresponding to mild, moderate, or severe IBS).
* Participant is 18-21 years of age at the time of consent.
* Participant is able to speak, read, and understand English.
* Participant is capable and willing to complete questionnaires, track symptoms, and complete exercises associated with use of Mahana™ IBS.
* Participant has unrestricted access to an iOS (running iOS 13 or later) or Android smartphone with internet connectivity and sufficient space for Mahana™ IBS to be installed.
* If participant is taking any prescription IBS-related concomitant medications, he/she must have been on a stable dose/regimen for at least 30 days prior to the date of Screening/Enrollment and is not intended to make changes to dose or regimen during the treatment period (i.e., through Week 12 of the study).

Exclusion Criteria:

* Participant has a medical or psychiatric comorbidity that might account for GI symptoms, confound the measurement of IBS symptoms, or compromise the participant's ability to complete the study (ex. inflammatory bowel disease, chronic liver disease, substance abuse disorder, etc.) in the opinion of the investigator.
* Participant is currently using opioids or plans to use for chronic pain management and/or recreation.
* Participant has been hospitalized for psychiatric reasons within 12 months prior to screening.
* Participant is currently experiencing high depression symptom severity as indicated by a score \>14 on the PHQ-8.
* Participant is currently experiencing suicidal ideation as indicated by a score of 2 or 3 on item 9 of the Beck Depression Index (BDI). \*
* Participant is currently using any prescription digital therapeutic that delivers components of cognitive-behavioral therapies.
* Participant has undergone CBT, any other skills-based, or GI-specific psychological therapy (e.g. Dialectical Behavioral Therapy, Acceptance and Commitment Therapy, Behavioral Activation, Problem-solving Therapy, Gut-Directed Hypnotherapy, etc.) within 2 years of study entry.
* Participant has participated in any investigational trial within 30 days prior to Screening or plans to participate in another clinical trial during the study period.
* Participant is currently pregnant or nursing.

Primary outcomes:
measure: Change in IBS Severity Scoring System from Baseline to Week 12
timeFrame: 12 Weeks
Secondary outcomes:
measure: Subject's Global Assessment of Relief at Week 12
timeFrame: 12 Weeks
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: Carolina Institute for Clinical Research
state: North Carolina
Study officials:
References: